"Men"

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.

Every September is the "World Alzheimer's Disease Month". In 2022, the theme of "World Alzheimer's Disease Month" is "Know Dementia, Know Alzheimer's - Another, we can do so much". It aims to continue to focus on early screening and early diagnosis, and focus on publicizing the 10 early symptoms, 12 risk factors that can be intervened and medical and social support after diagnosis of Alzheimer's disease, so as to achieve the goal of overall management of Alzheimer's disease

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

The prostate may be small, but its function is important. Don't be sedentary, don't hold your urine, and live a regular life is a good way to protect your prostate.

Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.

Approval for new FIC depression drug on the horizon!

Leukaemia is a very complex disease that causes fever and infection and bleeding, so it needs to be treated early so that it can be gradually controlled and the patient's symptoms can be gradually relieved

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours